Technical Analysis for BNOX - Bionomics Limited

Grade Last Price % Change Price Change
F 0.20 -1.06% 0.00
BNOX closed down 1.06 percent on Friday, November 1, 2024, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -1.06%
NR7 Range Contraction -1.06%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 22 hours ago
Possible Inside Day about 22 hours ago
Down 5% 1 day ago
Lower Bollinger Band Support 1 day ago
Down 3% 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bionomics Limited Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Cancer Treatment Monoclonal Antibodies Stem Cell Alzheimer's Disease Antineoplastic Drugs Central Nervous System Disorders Post Traumatic Stress Disorder Cognitive Impairment Treatment Of Central Nervous System Disorders Camidanlumab Tesirine Anxiolytics Milatuzumab

Is BNOX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.7874
52 Week Low 0.177
Average Volume 680,300
200-Day Moving Average 0.79
50-Day Moving Average 0.46
20-Day Moving Average 0.26
10-Day Moving Average 0.25
Average True Range 0.05
RSI (14) 31.03
ADX 39.93
+DI 13.65
-DI 32.49
Chandelier Exit (Long, 3 ATRs) 0.24
Chandelier Exit (Short, 3 ATRs) 0.31
Upper Bollinger Bands 0.35
Lower Bollinger Band 0.18
Percent B (%b) 0.11
BandWidth 64.56
MACD Line -0.07
MACD Signal Line -0.07
MACD Histogram 0.0024
Fundamentals Value
Market Cap 1.61 Million
Num Shares 8.16 Million
EPS -2.34
Price-to-Earnings (P/E) Ratio -0.08
Price-to-Sales 12.21
Price-to-Book 0.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.22
Resistance 3 (R3) 0.21 0.21 0.21
Resistance 2 (R2) 0.21 0.20 0.21 0.21
Resistance 1 (R1) 0.20 0.20 0.20 0.20 0.21
Pivot Point 0.19 0.19 0.19 0.19 0.19
Support 1 (S1) 0.19 0.19 0.18 0.19 0.18
Support 2 (S2) 0.18 0.19 0.18 0.18
Support 3 (S3) 0.18 0.18 0.18
Support 4 (S4) 0.18